Results 291 to 300 of about 4,357,163 (359)
Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. [PDF]
DiLeo M +12 more
europepmc +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc +1 more source
Multidimensional Assessment of Neurological Adverse Reactions Related to PD-1 Inhibitors: A Real-World Pharmacovigilance Study. [PDF]
Hu X +12 more
europepmc +1 more source
Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma. [PDF]
Harbi E +11 more
europepmc +1 more source
Remarkable Prolongation of Irreversible APTT and Non-Significant Hemorrhage: A Rare High Titer of FVIII Inhibitor Case Report and Literature Review. [PDF]
Zhang KH, Lu SS, Gao PL, Fu XY, Dong GY.
europepmc +1 more source

